Degradation of mutant p53H175 protein by Zn(II) through autophagy

Cell Death and Disease

Volumn 5, Issue 5, 2014, Pages

  Garufi, A ^a,b   Pucci, D ^c   D'Orazi, V ^d   Cirone, M ^e   Bossi, G ^a   Avantaggiati, M L ^f   D'Orazi, G ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CALABRIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f GEORGETOWN UNIVERSITY   (United States)

Author keywords

Autophagy; Cancer; Cloroquine; DRAM; LC3 II; p53; Zn(II)

Indexed keywords

CURCUMIN; PROTEASOME; PROTEIN P53; ZINC; MAP1LC3A PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; SMALL INTERFERING RNA; ZINC DERIVATIVE;

ARTICLE; AUTOPHAGY; CANCER CELL; CONTROLLED STUDY; DAMAGE REGULATED AUTOPHAGY MODULATOR GENE; DOWN REGULATION; GENE; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENETICS; HCT116 CELL LINE; METABOLISM; MUTATION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

AUTOPHAGY; CELL LINE, TUMOR; CURCUMIN; DOWN-REGULATION; HCT116 CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; ZINC COMPOUNDS;

EID: 84916924623     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.217     Document Type: Article

References (55)

1. Vousden KH, Lane DP. P53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
2. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
3. Muller PAJ, Vousden KH. P53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
4. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
5. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53 and cancerassociated mutants. Adv Cancer Res 2007; 97: 1-23.
6. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
7. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
8. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285-295.
9. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001; 276: 39359-39367.
10. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
11. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
12. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
13. Hanel W, Marchenko N, Xu S, Xiaofeng YS, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 2013; 7: 898-909.
14. Jackson JG, Lozano G. The mutant p53 mouse as a pre-clinical model. Oncogene 2013; 32: 4325-4330.
15. Wiman KG. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010; 29: 4245-4252.
16. Brown CJ, Cheok CF, Verma CS, Lane DP. Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 2011; 32: 53-62.
17. Mizushima N. Autophagy: process and function. Genes Dev 2007; 21: 2861-2873.
18. Glick D, Barth S, Mcleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010; 221: 3-12.
19. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A et al. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle 2012; 11: 4436-4446.
20. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
21. Choudhury S, Kolukula VK, Preet A, Albanese C, Avantaggiati ML. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle 2013; 12: 1022-1029.
22. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E et al. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res 2008; 68: 3707-3714.
23. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D et al. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp Cell Res 2009; 315: 67-75.
24. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C et al. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011; 10: 1679-1689.
25. Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C et al. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer 2012; 131: 562-568.
26. D'Orazi G, Givol D. p53 reactivation: the link to zinc. Cell Cycle 2012; 11: 2581-2582.
27. Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D'Orazi V et al. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res 2013; 32: 72.
28. Pucci D, Bellini T, Crispini A, D'Agnano I, Liguori PF, Garcia-Orduna P et al. DNA binding and cytotoxicity of fluorescent curcumin-based Zn(II) complexes. Med Chem Commun 2012; 3: 462-468.
29. Pucci D, Crispini A, Mendiguchía BS, Pirillo S, Ghedini M, Morelli S et al. Improving the bioactivity of Zn(II)-curcumin based complexes. Dalton Trans 2013; 42: 9679-9687.
30. Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004; 23: 2330-2338.
31. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737.
32. Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol 2010; 221: 117-124.
33. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol 2011; 27: 107-132.
34. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008; 7: 3056-3061.
35. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR et al. DRAM, a p53- induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121-134.
36. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
37. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 246-251.
38. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1: 68-76.
39. Bykov VJ, Lamber JM, Hainaut P, Wiman KG. Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 2009; 8: 16.
40. Yan W, Zhang Y, Zhang J, Liu S, Cho J, Chen X. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J Biol Chem 2011; 286: 17478-17486.
41. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cells through abrogation of mutant p53 expression. Oncogene 2006; 25: 304-309.
42. Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 2008; 7: 1870-1879.
43. Alarcon-Vargas D, Ronai Z. p53-Mdm2: the affair that never ends. Carcinogenesis 2002; 23: 541-547.
44. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol 2007; 27: 8284-8295.
45. Wang X, Di Pasqua AJ, Govind S, McCracken E, Hong C, Mi L et al. Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and its structure-activity relationships. J Med Chem 2011; 54: 809-816.
46. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-1602.
47. Jing K, Song KS, Shin S, Kim N, Jeong S, Oh HR et al. Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. Autophagy 2011; 7: 1348-1358.
48. Butler JS, Loh SN. Structure, function and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry 2003; 42: 2396-2403.
49. Loh SN. The missing zinc: p53 misfolding and cancer. Metallomics 2010; 2: 442-449.
50. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell 2012; 21: 614-625.
51. Morita A, Ariyasu S, Ohya S, Takahashi I, Wang B, Tanaka K et al. Evaluation of Zinc (II) chelators for inhibiting p53-mediated apoptosis. Oncotarget 2013; 4: 2439-2450.
52. Bhutia SK, Mukhopadhyay S, Sinha N, Das DN, Panda PK, Patra SK et al. Autophagy: cancer's friend or foe? Adv Cancer Res 2013; 118: 61-95.
53. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17: 654-666.
54. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987; 7: 2754-2756.
55. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. Targeting hypoxia in cancer cells by restoring homeodomain-interacting protein kinase-2 and p53 activity and suppressing HIF-1alpha. PLoS One 2009; 4: e6819.